NEKTAR THERAPEUTICS 8-K

What Happened

• On February 10, 2026, Nektar Therapeutics filed a Form 8-K (Item 7.01, Regulation FD disclosure) announcing that it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. The company said this figure is an estimate based solely on information available as of the announcement date and is not a comprehensive statement of its operating results or financial position for that date.

Key Details

• Filing: Form 8-K, Item 7.01 (Regulation FD disclosure), filed February 10, 2026.
• Cash and investments: approximately $229.1 million as of January 31, 2026.
• Basis: Amounts are estimates based on information available to the company on the announcement date.
• Not comprehensive: Company stated the figures do not constitute a full statement of operating results or financial position as of that date.

Why It Matters

• This disclosure gives investors a current snapshot of Nektar’s liquidity position (cash and marketable securities) but is not a substitute for audited or complete quarterly/annual financial statements. Investors should treat this as a high-level liquidity update and look to the company’s upcoming periodic reports (e.g., Form 10-Q/10-K) for complete financial results and context.